Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.22 +3.01%

+$0.81 today

Market cap
$1.76B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 3.12M

Average 1.81M

Returns on capital

Ultragenyx Pharmaceutical Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

718.8%

avg -22.1%

ROIC

-43.5%

avg -44.3%

ROA

-37.5%

avg -36.2%

Analysis

ROE is currently the strongest return metric at 718.8% versus its period average of -22.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Emil D. Kakkis

Founder, President, Chief Executive Officer & DirectorUSD 1.19M66132.69K0.13%

Erik Harris

Executive Vice President & Chief Commercial OfficerUSD 925.26K5649.96K0.05%

John Richard Pinion

Chief Quality Operations Officer & Executive Vice President of Translational SciencesUSD 923.93K6079.94K0.08%

Eric Crombez

Chief Medical Officer & Executive Vice PresidentUSD 882.36K53111.19K0.11%

Howard Horn

Executive Vice President of Corporate Strategy & Chief Financial OfficerUSD 846.01K4789.23K0.09%

Karah Herdman Parschauer

Chief Legal Officer & Executive Vice President of Corporate AffairsUSD 819.87K4892.56K0.09%

Dennis Karl Huang

Chief Technical Operations Officer and Executive Vice President of Gene Therapy OperationsUSD 331.33K6179.94K0.08%

Ernie W. Meyer

Chief Human Resources Officer & Executive Vice President—61——

Theodore A. Huizenga

Senior Vice President, Corporate Controller & Principal Accounting Officer—55——

Vimal Srivastava

Senior Vice President of Business Development & Alliance Management—61——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 15, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

28

$3.81M

Net Transaction Value

−$3.81M

Net selling

Most Active

Horn Howard

12 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 15, 26

Horn Howard

Direct

Sell$107.9K
Sep 15, 26

Huizenga Theodore Alan

Direct

Sell$17.4K
Sep 3, 26

Huizenga Theodore Alan

Direct

Sell$2.3K
Aug 3, 26

Horn Howard

Direct

Sell$117K
Aug 3, 26

Parschauer Karah Herdman

Direct

Sell$47.3K
Jul 1, 26

Horn Howard

Direct

Sell$155.6K
Jun 15, 26

Sanders Corazon (Corsee) D.

Direct

Sell$50.1K
Jun 15, 26

Parschauer Karah Herdman

Direct

Sell$46.8K
Jun 1, 26

Horn Howard

Direct

Sell$110.6K
May 18, 26

SULIMAN SHEHNAAZ

Direct

Sell$144.2K

1–10 of 28

Summary

Insiders reported 0 buys worth $0.00 and 28 sells worth $3.81M over the last 12 months. That adds up to net selling of $3.81M. Horn Howard was the most active insider with 12 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A11 analysts
RevenueN/AN/A+22.8%
+15.2% (5yr)7 analysts
Net IncomeN/AN/AN/A
N/A7 analysts
EBITN/AN/AN/A
N/A7 analysts

Analysis

Recent growth has been strongest in Revenue at +22.8% over three years. Forward estimates point to Revenue at +15.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Ultragenyx Pharmaceutical Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about RARE's management, answered from reported figures.

Who manages RARE?

Ultragenyx Pharmaceutical Inc. (RARE) lists 10 active executives. The top listed executive is Ernie W. Meyer, Chief Human Resources Officer & Executive Vice President.

Are RARE insiders buying or selling?

Recent insider activity shows net buying of $27.09M.